Status asthmaticus is a life-threatening condition with a high mortality rate of up to 10.3% [1]. Milger et al. recently described a rapid clinical improvement and a reduction in serum IgE levels in a patient with status asthmaticus who received salvage therapy with omalizumab [2]. This treatment is not approved for status asthmaticus. Therefore, the authors based their dose finding on the recommendations approved by the by the European Medicines Agency for the treatment of severe persistent allergic asthma. For this indication the maximum dose generally does not include an option for patients with a higher body weight and high IgE levels [2]. A significant number of patients with persistent severe allergic asthma cannot be treated because there are insufficient data to support the administration of omalizumab above the recommended maximum dose of 600mg every 2 weeks [3]. In contrast, there is a lot of evidence in the existing literature for a very good safety profile for omalizumab [4,5]. Here we report for the first time the successful treatment of a patient with refractory status asthmaticus by salvage therapy with updosed omalizumab adjusted for actual baseline IgE level, body weight and effect.
Background: In addition to clinical examinations, confirmatory investigations are frequently performed to determine brain death (BD). Among other perfusion tests, brain perfusion scintigraphy (BPS) has been shown to be a reliable tool for the detection of brain circulatory arrest, particularly in cases with inconclusive clinical status or potential pharmacological interactions. Methods: Evaluation for brain death included standardized clinical examinations by two experienced neuro-intensive medicine specialists, followed by ancillary brain perfusion tests. BPS with the lipophilic tracer 99mTc-hexamethylpropyleneamine oxime (HMPAO) was performed according to a standardized protocol. Imaging results, additional confirmatory test results, as well as clinical parameters were prospectively recorded. Results: BPS was performed in 30 patients (18 male, 12 female; median age 55.5 years, range 0.1–79.8 years). Eight patients underwent decompressive craniectomy (DC) prior to BD evaluation, three patients were supported by veno-arterial extracorporeal membrane oxygenation (vaECMO), and one patient by a left ventricular assist device (LVAD). The median interval between the initial brain-damaging event and BPS was 4.0 days (range 1–18 days). BPS demonstrated brain perfusion cessation in all patients. A concomitant single-photon emission computed tomography (SPECT) was required in one patient. There were no technical failures requiring a re-examination. Conclusions: BPS is a feasible, safe, and technically robust confirmatory test in BD diagnosis. BPS yielded unambiguous results, particularly in cases with inconclusive results of other ancillary tests, in neonates, young children and patients after DC. It is applicable to patients supported by LVAD and vaECMO.